医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2013年
18期
282-282
,共1页
冠心病心绞痛%通心络胶囊%血脂变化
冠心病心絞痛%通心絡膠囊%血脂變化
관심병심교통%통심락효낭%혈지변화
Coronary heart disease%Angina%Tongxinluo capsule%Clinical analysis
目的探讨通心络胶囊对冠心病心绞痛的临床疗效。方法选取186例冠心病心绞痛患者,随机分为对照组和观察组,每组93例,对照组给予常规西药治疗,观察组在对照组的基础上给予通心络胶囊。连续应用4w后,对两组患者心绞痛、心电图及血脂指标进行分析。结果①心绞痛改善情况:观察组总有效率显著高于对照组(P<0.05)。②心电图改善情况:观察组总有效率显著高于对照组(P<0.05)。③治疗前后血脂水平变化:治疗后血清总胆固醇、甘油三酯显著下降,观察组下降更为明显(P<0.05);治疗后两组患者高密度脂蛋白胆固醇显著升高,低密度脂蛋白胆固醇显著降低,治疗组变化略优于对照组(P>0.05)。结论通心络胶囊可降低血脂,延缓动脉粥样硬化进程,是治疗冠心病心绞痛的可靠药物。
目的探討通心絡膠囊對冠心病心絞痛的臨床療效。方法選取186例冠心病心絞痛患者,隨機分為對照組和觀察組,每組93例,對照組給予常規西藥治療,觀察組在對照組的基礎上給予通心絡膠囊。連續應用4w後,對兩組患者心絞痛、心電圖及血脂指標進行分析。結果①心絞痛改善情況:觀察組總有效率顯著高于對照組(P<0.05)。②心電圖改善情況:觀察組總有效率顯著高于對照組(P<0.05)。③治療前後血脂水平變化:治療後血清總膽固醇、甘油三酯顯著下降,觀察組下降更為明顯(P<0.05);治療後兩組患者高密度脂蛋白膽固醇顯著升高,低密度脂蛋白膽固醇顯著降低,治療組變化略優于對照組(P>0.05)。結論通心絡膠囊可降低血脂,延緩動脈粥樣硬化進程,是治療冠心病心絞痛的可靠藥物。
목적탐토통심락효낭대관심병심교통적림상료효。방법선취186례관심병심교통환자,수궤분위대조조화관찰조,매조93례,대조조급여상규서약치료,관찰조재대조조적기출상급여통심락효낭。련속응용4w후,대량조환자심교통、심전도급혈지지표진행분석。결과①심교통개선정황:관찰조총유효솔현저고우대조조(P<0.05)。②심전도개선정황:관찰조총유효솔현저고우대조조(P<0.05)。③치료전후혈지수평변화:치료후혈청총담고순、감유삼지현저하강,관찰조하강경위명현(P<0.05);치료후량조환자고밀도지단백담고순현저승고,저밀도지단백담고순현저강저,치료조변화략우우대조조(P>0.05)。결론통심락효낭가강저혈지,연완동맥죽양경화진정,시치료관심병심교통적가고약물。
Objective To investigate the ef iciency and feasibility of Tongxinluo capsules in treatmentof coronary heart disease.Methods 186 patients with angina caused by coronary heart disease were randomlydivided into experimental group (n=93)and control group (n=93).Al patients were treated according to conventional lipid disease,relief, anti-angina medication.The experimental group were treated with Tongxinluo capsule addition.After 4 weeks,index of ef iciency were analyzed.Results①The improving situation of angina:the total cure rates was higher in experimental group than control group (P<0.05). The improving situation of ECG:the total cure rates was higher in experimental group than control group (P<0.05).③lipid levels before and after treatment:After treatment, serum total cholesterol, triglycerides decreased significantly in the experimental group decreased more significantly (P<0.05);After treatment, high-density lipoprotein cholesterol increased significantly, low-density lipoprotein cholesterol significantly lower in the experimental group than the control group slightly change (P>0.05). Conclusion Tongxinluo capsule is ef iciency and feasibility in treating coronary heart disease.